Christine McSherry founded Jett Foundation in 2001, when her son now 20-year-old Jett was diagnosed with Duchenne Muscular Dystrophy. As head of the Jett Foundation, Christine co-founded the International Duchenne Alliance, a partnership of over 40 independent organizations that has funded nearly $15 million dollars in research to date. Christine has advocated for the patient perspective to be considered by the FDA when reviewing safe and potentially effective treatments for Duchenne. In April of 2016, Christine presented the Jett Foundation's Patient Centered Outcomes report at the FDA's meeting of the Peripheral and Central Nervous System Drugs Advisory Committee.
Mindy's background in project management, software development, and information architecture came in handy when designing a PRO program for her son, Aidan, a 14-year-old with Duchenne Muscular Dystrophy. That PRO program then proved instrumental in the approval of EXONDYS51, the first FDA-approved treatment for Duchenne. When Aidan's insurance company denied coverage for EXONDYS, the data Mindy captured overturned the denial in 24 hours without engaging in the appeal process.
Senior Research Scientist
Director of Quality
Strategy and Business Development
Clinical Operations Consultant
Director of Operations